Analysts Set Expectations for PCRX Q1 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Pacira BioSciences in a note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao anticipates that the company will earn $0.21 per share for the quarter. HC Wainwright has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share. HC Wainwright also issued estimates for Pacira BioSciences’ Q2 2027 earnings at $0.37 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.49 EPS and FY2027 earnings at $1.49 EPS.

Several other analysts have also recently issued reports on PCRX. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Zacks Research lowered shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. Barclays dropped their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Finally, Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.25.

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $22.60 on Wednesday. The company’s 50-day moving average price is $22.02 and its 200-day moving average price is $23.29. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. The company has a market cap of $915.07 million, a P/E ratio of 150.67 and a beta of 0.21. Pacira BioSciences has a twelve month low of $18.80 and a twelve month high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The business had revenue of $196.87 million for the quarter, compared to analyst estimates of $201.93 million. During the same period last year, the firm earned $0.91 EPS. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year.

Insider Buying and Selling at Pacira BioSciences

In other news, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the sale, the senior vice president directly owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 3,261 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the transaction, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 8,677 shares of company stock valued at $191,980. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC grew its holdings in shares of Pacira BioSciences by 7.7% in the fourth quarter. Hsbc Holdings PLC now owns 18,416 shares of the company’s stock valued at $479,000 after purchasing an additional 1,316 shares in the last quarter. Vident Advisory LLC increased its stake in Pacira BioSciences by 15.0% during the 4th quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock worth $610,000 after buying an additional 3,075 shares during the period. Empowered Funds LLC lifted its holdings in Pacira BioSciences by 1.9% during the 4th quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock worth $5,890,000 after buying an additional 4,167 shares in the last quarter. XTX Topco Ltd acquired a new stake in Pacira BioSciences during the 4th quarter worth approximately $2,146,000. Finally, Millennium Management LLC boosted its position in Pacira BioSciences by 73.3% in the 4th quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock valued at $3,173,000 after buying an additional 51,848 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.